A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 20,000 shares of CUE stock, worth $20,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 22,200 9.91%
Holding current value
$20,000
Previous $28,000 46.43%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$0.45 - $1.08 $990 - $2,376
-2,200 Reduced 9.91%
20,000 $15,000
Q3 2023

Oct 24, 2023

BUY
$2.23 - $4.69 $4,906 - $10,318
2,200 Added 11.0%
22,200 $51,000
Q2 2023

Jul 13, 2023

BUY
$3.11 - $4.91 $62,200 - $98,200
20,000 New
20,000 $73,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $35.4M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.